User profiles for Guido Moll
Guido MollCharité Universitätsmedizin Berlin Verified email at charite.de Cited by 4605 |
RETRACTED: tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study
…, B Leidner, T Lilja, J Liska, T Luedde, V Lundin, G Moll… - The lancet, 2011 - thelancet.com
Background Tracheal tumours can be surgically resected but most are an inoperable size at
the time of diagnosis; therefore, new therapeutic options are needed. We report the clinical …
the time of diagnosis; therefore, new therapeutic options are needed. We report the clinical …
Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal/stem cells and other common cellular therapeutics
…, A Lipat, C Turner-Lyles, J Nguyen, G Moll… - Current stem cell …, 2022 - Springer
Purpose of Review Cryopreservation and its associated freezing and thawing procedures–short
“freeze-thawing”–are among the final steps in economically viable manufacturing and …
“freeze-thawing”–are among the final steps in economically viable manufacturing and …
Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?
G Moll, JJ Alm, LC Davies, L von Bahr, N Heldring… - Stem …, 2014 - academic.oup.com
We have recently reported that therapeutic mesenchymal stromal cells (MSCs) have low
engraftment and trigger the instant blood mediated inflammatory reaction (IBMIR) after systemic …
engraftment and trigger the instant blood mediated inflammatory reaction (IBMIR) after systemic …
Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements
J Doorn, G Moll, K Le Blanc… - … Engineering Part B …, 2012 - liebertpub.com
Among the various types of cell-to-cell signaling, paracrine signaling comprises those signals
that are transmitted over short distances between different cell types. In the human body, …
that are transmitted over short distances between different cell types. In the human body, …
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial
A Roemhild, NM Otto, G Moll, M Abou-El-Enein… - bmj, 2020 - bmj.com
Objective To assess whether reshaping of the immune balance by infusion of autologous
natural regulatory T cells (nTregs) in patients after kidney transplantation is safe, feasible, and …
natural regulatory T cells (nTregs) in patients after kidney transplantation is safe, feasible, and …
Are therapeutic human mesenchymal stromal cells compatible with human blood?
G Moll, I Rasmusson-Duprez, L von Bahr… - Stem …, 2012 - academic.oup.com
Multipotent mesenchymal stromal cells (MSCs) are tested in numerous clinical trials. Questions
have been raised concerning fate and function of these therapeutic cells after systemic …
have been raised concerning fate and function of these therapeutic cells after systemic …
Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines
Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal
stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated …
stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated …
Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses
G Moll, R Jitschin, L von Bahr, I Rasmusson-Duprez… - PloS one, 2011 - journals.plos.org
Infusion of human third-party mesenchymal stromal cells (MSCs) appears to be a promising
therapy for acute graft-versus-host disease (aGvHD). To date, little is known about how …
therapy for acute graft-versus-host disease (aGvHD). To date, little is known about how …
Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy?
Mesenchymal stromal cells (MSCs) harbor great therapeutic potential for numerous
diseases. From early clinical trials, success and failure analysis, bench-to-bedside and back-to-…
diseases. From early clinical trials, success and failure analysis, bench-to-bedside and back-to-…
Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua
While therapeutic mesenchymal stromal/stem cells (MSCs) have usually been obtained from
bone marrow, perinatal tissues have emerged as promising new sources of cells for stromal …
bone marrow, perinatal tissues have emerged as promising new sources of cells for stromal …